黄芪丹参合剂治疗PCI术后冠心病患者的临床疗效  

Clinical effect of HuangQi–Danshen mixture in the treatment of coronary heart disease patients after PCI

作　　者：陈一坚 陈宇凯[1] 周平[1] CHEN Yijian;CHEN Yukai;ZHOU Ping(Department of Cardiovascular Medicine,Affiliated Hospital of Hangzhou Normal University,Hangzhou 310015,China)

机构地区：[1]杭州师范大学附属医院心血管内科,浙江杭州310015

出　　处：《中国现代医生》2022年第24期80-83,共4页China Modern Doctor

基　　金：浙江省中医药科技计划(2016ZA165)。

摘　　要：目的 探讨黄芪丹参合剂治疗经皮冠状动脉介入(percutaneous coronary intervention,PCI)术后冠心病患者的临床疗效。方法 采用前瞻性研究方法,纳入2019年1月至2020年12月杭州师范大学附属医院收治的行PCI术治疗的冠心病患者90例,采用随机数表法将其分为对照组和观察组,每组各45例。其中对照组患者给予常规西医康复治疗,观察组患者在对照组基础上加用黄芪丹参合剂。比较分析两组患者治疗前后B型钠尿肽(B natriuretic peptide,BNP)水平、炎症因子水平、简明健康状况调查问卷–36(SF–36)评分及主要心血管不良事件(major cardiovascular adverse events,MACE)发生率。结果 观察组患者治疗后BNP水平显著低于对照组、治疗前,差异有统计学意义(P<0.05);观察组治疗后炎症因子水平均显著低于对照组、治疗前,差异有统计学意义(P<0.05);观察组治疗后SF–36评分均显著高于对照组、治疗前,差异有统计学意义(P<0.05);观察组随访3个月MACE发生率显著低于对照组,差异有统计学意义(P<0.05)。结论 冠心病患者PCI术后加用黄芪丹参合剂可有效保护心脏功能,减轻心肌炎性反应水平,提高生活质量,并有助于预防MACE发生。Objective To investigate the clinical effect of HuangQi–Danshen mixture in the treatment of coronary heart disease patients after percutaneous coronary intervention(PCI). Methods 90 patients with coronary heart disease after PCI were rprospectively chosen in the period from January 2019 to December 2020 in Affiliated Hospital of Hangzhou Normal University and divided by random number table method into control group and observation group,45 cases in each group. Control group with conventional western medicine rehabilitation treatment, observation group HuangQi–Danshen mixture on the basis of control group;and the levels of B natriuretic peptide(BNP), inflammatory cytokines index, SF–36 score, and incidence of major adverse cardiovascular events(MACE) before and after treatment of two groups were compared. Results The levels of BNP after treatment of observation group were significantly less than control group and before treatment, the differences were statistically significant(P<0.05). The levels of inflammatory cytokines after treatment of observation group were significantly more than control group and before treatment, the differences were statistically significant(P<0.05). The SF–36 scores after treatment of observation group were significantly more than control group and before treatment, the differences were statistically significant(P<0.05). The MACE incidence in 3 months follow–up of observation group was significantly less than control group,the difference was statistically significant(P<0.05). Conclusion HuangQi–Danshen mixture in the treatment of patients with coronary heart disease after PCI can efficiently improve the cardiac function, reduce the levels of myocardial inflammation, improve the quality of life, and be helpful to prevent the occurrence of MACE.

关 键 词：黄芪丹参合剂 冠心病 经皮冠状动脉介入 生活质量 

分 类 号：R259[医药卫生—中西医结合]